The liver and the kidney: Mutual clearance or mixed intoxication

Contributions to Nephrology

Volumn 156, Issue , 2007, Pages 17-23

  Arroyo, Vicente ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMINOID; ANTIINFECTIVE AGENT; VASOCONSTRICTOR AGENT;

ARTICLE; HEPATORENAL SYNDROME; HUMAN; KIDNEY; LIVER; LIVER TRANSPLANTATION; MICROBIOLOGY; MULTIPLE ORGAN FAILURE; PATHOLOGY; PATHOPHYSIOLOGY; PERITONITIS; PHYSIOLOGY; VASCULARIZATION; VASOCONSTRICTION; VASODILATATION;

ALBUMINS; ANTI-INFECTIVE AGENTS; HEPATORENAL SYNDROME; HUMANS; KIDNEY; LIVER; LIVER TRANSPLANTATION; MULTIPLE ORGAN FAILURE; PERITONITIS; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 34247590562     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/0000102011     Document Type: Article

References (14)

1. Gines A, Escorsell A, Gines P, et al: Incidence, predictive factors, and prognosis of the hepatorenal-syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-236.
2. Navasa M, Follo A, Filella X, et al: Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998;27:1227-1232.
3. Follo A, Llovet JM, Navasa M, et al: Renal impairment after spontaneous bacterial peritonitis in cirrhosis - incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:1495-1501.
4. Toledo C, Salmeron JM, Rimola A, et al: Spontaneous bacterial peritonitis in cirrhosis - predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 1993;17:251-257.
5. Ruiz-del-Arbol L, Urman J, Fernandez J, et al: Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210-1218.
6. Terra C, Guevara M, Torre A, et al: Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005;129:1944-1953.
7. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al: Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42:439-447.
8. Navasa M, Fernandez J, Montoliu S, et al: Randomized, double-blind, placebo, controlled trial evaluating norfloxacin in the primary prophylaxis of spontaneous bacterial peritonitis in cirrhotics with renal impairment, hyponatremia or severe liver failure (abstract). J Hepatol 2006;44:S51.
9. Sort P, Navasa M, Arroyo V, et al: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-409.
10. Fernandez J, Monteagudo J, Bargallo X, et al: A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005;42:627-634.
11. Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB: Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome - experience in 300 patients. Transplantation 1991;51:428-430.
12. Uriz J, Gines P, Cardenas A, et al: Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33:43-48.
13. Ortega R, Gines P, Uriz J, et al: Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002;36:941-948.
14. Duvoux C, Zanditenas D, Hezode C, et al: Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002;36:374-380.